The Technical Analyst
IDEAYA Biosciences Inc [IDYA]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
IDEAYA Biosciences Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
2.51% $40.00
America/New_York / 24 apr 2024 @ 10:31
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 2 982.41 mill |
| EPS: | -1.960 |
| P/E: | -20.41 |
| Earnings Date: | May 07, 2024 |
| SharesOutstanding: | 74.56 mill |
| Avg Daily Volume: | 0.704 mill |
| RATING 2024-04-23 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Sell | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Sell | |
| P/E: | Strong Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -20.41 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -3.47x |
| Company: PE -20.41 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-0.114 (-100.29%) $-40.11 |
| Date: 2024-04-24 |
| Expected Trading Range (DAY) |
|---|
|
$ 38.39 - 41.85 ( +/- 4.31%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-01 | Hata Yujiro S | Buy | 480 000 | Stock Option (right to buy) |
| 2024-03-01 | Ruiz Briseno Andres | Buy | 85 000 | Stock Option (right to buy) |
| 2024-03-01 | Beaupre Darrin | Buy | 160 000 | Stock Option (right to buy) |
| 2024-03-01 | White Michael Anthony | Buy | 140 000 | Stock Option (right to buy) |
| 2024-03-01 | Throne Jason | Buy | 125 500 | Stock Option (right to buy) |
| INSIDER POWER |
|---|
| 41.91 |
| Last 100 transactions |
| Buy: 2 399 671 | Sell: 963 791 |
Forecast:
12:12 - $39.83
Live Trading Signals (every 1 min)
Forecast
1: 10:42 - $40.10
Forecast 2: 11:32 - $40.19
Forecast 3: 12:12 - $39.83
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $40.00 (2.51% ) |
| Volume | 0.0887 mill |
| Avg. Vol. | 0.704 mill |
| % of Avg. Vol | 12.59 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For IDYA
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $44.99 | N/A | Active |
|---|
IDYA
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Latest Press Releases
2024-04-24 10:05:00 - Press Release
Ideaya Biosciences Announces Asco 2024 Oral Presentation For Darovasertib In Neoadjuvant Uveal Melanoma Phase 2 Investigator Sponsored Study
Oral presentation at asco 2024 scheduled for monday, june 3, 2024, at 9:51 am cdt the abstract summary will be available on thursday, may 23, 2024 at ~5:00pm et south san francisco, calif. , april 24, 2024 /prnewswire/ -- ideaya biosciences, inc. (nasdaq: idya), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that interim results from the investigator-sponsored phase 2 trial evaluating darovasertib safety and efficacy as neoadjuvant/adjuvant treatment in uveal melanoma (um) have been selected for an oral presentation at the 2024 american society of clinical oncology (asco) annual meeting taking place may 31-june 4, 2024 in chicago, illinois.
2024-04-22 06:00:00 - Press Release
Ideaya Biosciences Announces Selection Of Move-forward Phase 2 Expansion Dose For Ide397 Monotherapy In Mtap-deletion Squamous Non-small Cell Lung Cancer
Selected a move-forward phase 2 expansion dose for ide397 monotherapy in mtap-deletion squamous nsclc, based on ae profile and preliminary clinical efficacy observed, including multiple partial responses by recist 1.1 evaluating over 40 mtap pdx preclinical models, squamous nsclc was identified as the most sensitive tumor type to ide397 monotherapy where ~50% of the models observed tumor regressions at 30mg/kg qd over 100,000 global annual incidence of mtap-deletion squamous nsclc south san francisco, calif. , april 22, 2024 /prnewswire/ -- ideaya biosciences, inc. (nasdaq: idya), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced selection of a move-forward phase 2 expansion dose for ide397 monotherapy in mtap-deletion squamous non-small cell lung cancer (nsclc), based on adverse event profile and preliminary clinical efficacy observed, including multiple partial responses by recist 1...
2024-04-05 06:00:00 - Press Release
Ideaya Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
South san francisco, calif., april 5, 2024 /prnewswire/ -- ideaya biosciences, inc. (nasdaq: idya), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on march 28, 2024, the compensation committee of ideaya's board of directors granted non-qualified stock options to purchase an aggregate of 70,000 shares of the company's common stock to two newly hired employees.
2024-04-01 06:00:00 - Press Release
Ideaya Biosciences To Participate In Upcoming April 2024 Investor Relations Event
South san francisco, calif. , april 1, 2024 /prnewswire/ -- ideaya biosciences, inc. (nasdaq: idya), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in an upcoming investor relations event.
2024-03-12 06:00:00 - Press Release
Ideaya Announces Clinical Collaboration To Evaluate Ide161 In Combination With Keytruda® (pembrolizumab) In Patients With Endometrial Cancer
�trial will evaluate ide161, ideaya's investigational parg inhibitor, in combination with keytruda ® (pembrolizumab), merck's anti-pd-1 therapy, in patients with msi-high and mss endometrial cancer potential first-in-class parg inhibitor, in combination with anti-pd-1 therapy, targets two complementary mechanisms of anti-tumor immune response in endometrial cancer ideaya will sponsor the clinical trial and merck will provide keytruda south san francisco, calif., march 12, 2024 /prnewswire/ -- ideaya biosciences, inc. (nasdaq:idya), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that it has entered into a clinical trial collaboration and supply agreement with merck (known as msd outside the us and canada) to evaluate ide161, the company's investigational, potential first-in-class, small molecule poly (adp-ribose) glycohydrolase, or parg, inhibitor, in combination with keytruda® (pembrolizumab) merck's anti-pd-1 therapy, in patients with microsatellite instability-, or msi-, high and microsatellite stable, or mss, endometrial cancer, in a phase 1 clinical trial.
Latest News
2024-01-15 08:16:07 - Zacks Investment Research
IDEAYA Biosciences, Inc. (IDYA) Moves 7.6% Higher: Will This Strength Last?
IDEAYA Biosciences, Inc. (IDYA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
2023-12-03 09:00:00 - PRNewsWire
IDEAYA Announces Agenda for Investor R&D Day Webcast on December 4, 2023
SOUTH SAN FRANCISCO, Calif. , Dec. 3, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced agenda topics for its Investor R&D Day.
2023-11-07 08:16:05 - Zacks Investment Research
IDEAYA Biosciences, Inc. (IDYA) Reports Q3 Loss, Lags Revenue Estimates
IDEAYA Biosciences, Inc. (IDYA) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.47. This compares to earnings of $0.04 per share a year ago.
2023-10-18 09:46:14 - Zacks Investment Research
IDEAYA Biosciences, Inc. (IDYA) Surges 7.6%: Is This an Indication of Further Gains?
IDEAYA Biosciences, Inc. (IDYA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
2023-09-13 06:19:05 - Seeking Alpha
IDEAYA's Triple Threat: Melanoma, Money, And Momentum
IDEAYA Biosciences specializes in precision oncology, has FDA clearance for a Phase 1/2 trial, and partnerships with Amgen and GSK. Financially stable with a 50-month cash runway, the company has multiple clinical and preclinical programs in its diversified pipeline. IDEAYA Biosciences has a strong financial position, diverse pipeline, and valuable partnerships, making it a recommended "Buy" in the biotech sector.
2023-08-10 08:30:08 - Zacks Investment Research
IDEAYA Biosciences, Inc. (IDYA) Reports Q2 Loss, Lags Revenue Estimates
IDEAYA Biosciences, Inc. (IDYA) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to loss of $0.57 per share a year ago.
2023-06-08 17:27:08 - Seeking Alpha
Ideaya Biosciences: Lots Of 'Shots On Goal' And Upcoming Potential Catalysts
Today, we take our first in-depth look at a developmental concerned called Ideaya Biosciences, Inc. Ideaya Biosciences is moving forward a diverse pipeline of drug candidates based on its focus on synthetic lethality. An investment analysis follows in the paragraphs below.
2023-05-24 22:33:03 - 24/7 Wall Street
Goldman Sachs Initiates Coverage of Ideaya Biosciences With Buy Recommendation
Fintel reports that on May 24, 2023, Goldman Sachs initiated coverage of Ideaya Biosciences (NASDAQ:IDYA) with a Buy recommendation.
2023-05-09 09:10:49 - Zacks Investment Research
IDEAYA Biosciences, Inc. (IDYA) Reports Q1 Loss, Misses Revenue Estimates
IDEAYA Biosciences, Inc. (IDYA) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to loss of $0.36 per share a year ago.
2023-04-25 06:52:04 - Zacks Investment Research
Strength Seen in IDEAYA Biosciences, Inc. (IDYA): Can Its 35.7% Jump Turn into More Strength?
IDEAYA Biosciences, Inc. (IDYA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.